Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia
类卵泡抑素 1 介导细菌性肺炎中的宿主防御
基本信息
- 批准号:10636904
- 负责人:
- 金额:$ 57.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAgonistAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAsthmaAutoimmunityBacterial Antibiotic ResistanceBacterial InfectionsBacterial PneumoniaBindingBiologyBronchoalveolar Lavage FluidCD14 AntigenCD14 geneCause of DeathCellsCessation of lifeChildClinicalComplexCritical PathwaysDataDevelopmentDiseaseFollistatinFollistatin-Related Protein 1GenesGenetic TranscriptionHealthHealth Care CostsHomeostasisHospitalizationHost DefenseImmuneImmune TargetingImmunityImmunomodulatorsImmunotherapyImpairmentIn VitroInfectionInflammatoryKlebsiella pneumoniaeKnockout MiceKnowledgeLeadLiteratureLungLung infectionsMalignant NeoplasmsMediatingMediatorModelingMolecularMorbidity - disease rateMusNF-kappa BNatural ImmunityNeutrophil InfiltrationNosocomial pneumoniaNuclear Hormone ReceptorsOutcome StudyPathogenesisPathway interactionsPhagocytosisPneumoniaPopulationPre-Clinical ModelPredispositionProductionPublic HealthPublicationsPublishingPulmonary EmphysemaPulmonary FibrosisRecombinantsResistance to infectionRespiratory BurstRoleSignal TransductionSurfaceSystemTLR4 geneTestingTherapeuticWild Type MouseWorkbactericideconditional knockoutcostextracellularimmune functionimmunomodulatory therapiesimprovedin vivoin vivo Modelinnovationlung developmentmortalitymucoidneutrophilnovelnovel strategiesnovel therapeutic interventionpathogenpneumonia modelpneumonia treatmentreceptorresponsetargeted treatmenttherapeutic targettool
项目摘要
Pneumonia is the leading cause of death in children and the leading infectious cause of
death in the U.S, costing more than $17 billion. Antibiotic resistance (AR) increasingly
complicates pneumonia treatment and poses a national and worldwide public health crisis.
Klebsiella pneumoniae, a common pneumonia-causing AR pathogen, is an excellent tool for
preclinical modeling of pulmonary immunity. While immune modulation therapies have
transformed the fields of cancer and autoimmunity, immunotherapy is undeveloped for the
treatment of bacterial infections including pneumonia.
We identified that follistatin-like 1 (FSTL-1) as is a novel host-immune gene critical for
pulmonary host defense. The FSTL-1 mediated effect required expression of nuclear hormone
receptor 4A1 (Nr4a1), a newly recognized determinant of K. pneumoniae (Kp) pulmonary
immunity. However, the mechanism underlying FSTL-1- and Nr4a1-mediated lung host defense
are unknown. Published literature and our preliminary data lead to the hypothesis that FSTL-
1, through CD14-binding, promotes pulmonary innate immunity against K. pneumoniae
by 1) directing neutrophil recruitment to the lung and 2) enhancing neutrophil-intrinsic,
Nr4a1-dependent bacterial killing, which will be tested via three Aims.
Aim 1) will elucidate the constituents of FSTL-1 mediated neutrophil recruitment to the
lung during K. pneumoniae infection using the Kp pneumonia model, will test whether FSTL-
1 -dependent neutrophil recruitment is immune cell-intrinsic, whether rFSTL-1-driven neutrophil
recruitment is mediated by the receptor CD14 and the cellular requirements therein, as well as
the cell-specific contribution of Nr4a1 in FSTL-1-mediated pulmonary immunity. Aim 2) will
determine how FSTL-1 enhances neutrophil-intrinsic bactericidal function by testing
whether neutrophil-intrinsic FSTL-1 expression is required antibacterial effector function, FSTL-
1-dependent neutrophil effector function (phagocytosis, oxidative burst/ROS production,
NETosis and the requirement of CD14 on neutrophils for this effect. Aim 3) will define the
therapeutic potential of targeting Nr4a1 during K. pneumoniae infection. This will examine
if Nr4a1-deficiency impairs neutrophil effector functions and whether Nr4a1 stimulating
treatment can be used to improve bacterial pneumonia.
Cumulatively, the proposed work will focus on filling an existing gap in knowledge: the
cellular and molecular constituents of FSTL-1-mediated pulmonary host-defense.
肺炎是导致儿童死亡的主要原因,也是儿童感染的主要原因。
死亡在美国,成本超过170亿美元。抗生素耐药性(AR)日益严重
使肺炎治疗复杂化,并造成国家和世界范围的公共卫生危机。
肺炎克雷伯氏菌是一种常见的肺炎致AR病原体,
肺免疫的临床前建模。虽然免疫调节疗法具有
虽然免疫疗法改变了癌症和自身免疫领域,但免疫疗法尚未开发,
治疗细菌感染,包括肺炎。
我们发现卵泡抑素样1(FSTL-1)是一个新的宿主免疫基因,
肺宿主防御FSTL-1介导的作用需要核激素的表达
受体4A 1(Nr 4a 1)是新近发现的K.肺炎(Kp)肺
免疫力然而,FSTL-1和Nr 4a 1介导的肺宿主防御的潜在机制,
是未知的。已发表的文献和我们的初步数据导致的假设,FSTL-
1通过与CD 14结合,促进肺天然免疫。肺炎
通过1)引导中性粒细胞募集到肺和2)增强中性粒细胞-内源性,
Nr 4a 1依赖性细菌杀伤,将通过三个目标进行测试。
目的1)将阐明FSTL-1介导的中性粒细胞募集到细胞的组成部分,
K.使用Kp肺炎模型的肺炎感染,将测试FSTL-
1依赖的中性粒细胞募集是免疫细胞内在的,无论是rFSTL-1驱动的中性粒细胞
募集由受体CD 14和其中的细胞需求介导,以及
Nr 4a 1在FSTL-1介导的肺免疫中的细胞特异性贡献。(2)将
通过测试确定FSTL-1如何增强嗜中性粒细胞固有的杀菌功能,
是否需要抗菌素-内在FSTL-1表达的抗菌效应功能,FSTL-
1-依赖性中性粒细胞效应子功能(吞噬作用,氧化爆发/ROS产生,
NETosis和中性粒细胞上的CD 14对于这种作用的需求。目标3)将定义
在K.肺炎感染。这将检查
如果Nr 4a 1缺乏损害中性粒细胞效应子功能,
治疗可用于改善细菌性肺炎。
拟议的工作将逐步侧重于填补现有的知识空白:
FSTL-1介导的肺宿主防御的细胞和分子成分。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRIAN T CAMPFIELD其他文献
BRIAN T CAMPFIELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRIAN T CAMPFIELD', 18)}}的其他基金
A Critical Role for Follistatin-like Protein-1 in Lung Homeostasis
卵泡抑素样蛋白 1 在肺稳态中的关键作用
- 批准号:
9495584 - 财政年份:2015
- 资助金额:
$ 57.93万 - 项目类别:
A Critical Role for Follistatin-like Protein-1 in Lung Homeostasis
卵泡抑素样蛋白 1 在肺稳态中的关键作用
- 批准号:
8947692 - 财政年份:2015
- 资助金额:
$ 57.93万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 57.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 57.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 57.93万 - 项目类别: